Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism

[1]  K. Chiam,et al.  Loss of p53 Enhances NF‐κB‐Dependent Lamellipodia Formation , 2014 .

[2]  Zhuo-rong Li,et al.  Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction. , 2014, European journal of medicinal chemistry.

[3]  K. Chiam,et al.  Loss of p53 Enhances NF‐κB‐Dependent Lamellipodia Formation , 2014, Journal of cellular physiology.

[4]  B. Aggarwal,et al.  Targeting proteasomal pathways by dietary curcumin for cancer prevention and treatment. , 2014, Current medicinal chemistry.

[5]  D. Lane,et al.  Drugging the p53 pathway: understanding the route to clinical efficacy , 2014, Nature Reviews Drug Discovery.

[6]  Y. Wang,et al.  Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. , 2014, Journal of medicinal chemistry.

[7]  A. Gudkov,et al.  Peptides genetically selected for NF-κB activation cooperate with oncogene Ras and model carcinogenic role of inflammation , 2014, Proceedings of the National Academy of Sciences.

[8]  S. So,et al.  Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development. , 2014, ACS medicinal chemistry letters.

[9]  Jing Zhang,et al.  Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. , 2013, Journal of medicinal chemistry.

[10]  Hai-bin Luo,et al.  Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease. , 2013, Journal of medicinal chemistry.

[11]  E. Novellino,et al.  Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators. , 2013, Journal of medicinal chemistry.

[12]  Liu Liu,et al.  A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. , 2013, Journal of medicinal chemistry.

[13]  A. Palmeira,et al.  Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach. , 2013, Biochemical pharmacology.

[14]  I. Dolečková,et al.  Synthesis and biological evaluation of guanidino analogues of roscovitine. , 2013, European journal of medicinal chemistry.

[15]  L. Joosten,et al.  TREM‐1: intracellular signaling pathways and interaction with pattern recognition receptors , 2013, Journal of leukocyte biology.

[16]  S. V. van Heeringen,et al.  APR-246/PRIMA-1MET rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations , 2013, Proceedings of the National Academy of Sciences.

[17]  K. Wiman,et al.  Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET , 2013, Proceedings of the National Academy of Sciences.

[18]  H. Yokosawa,et al.  Siladenoserinols A-L: new sulfonated serinol derivatives from a tunicate as inhibitors of p53-Hdm2 interaction. , 2013, Organic letters.

[19]  G. Wahl,et al.  MDM2, MDMX and p53 in oncogenesis and cancer therapy , 2013, Nature Reviews Cancer.

[20]  S. Girardin,et al.  Nod-like receptors in intestinal host defense: controlling pathogens, the microbiota, or both? , 2013, Current opinion in gastroenterology.

[21]  P. Tak,et al.  The resolution of inflammation , 2012, Nature Reviews Immunology.

[22]  P. Grewal,et al.  Liver cancer and alcohol. , 2012, Clinics in liver disease.

[23]  J. Stauffer,et al.  Chronic inflammation, immune escape, and oncogenesis in the liver: A unique neighborhood for novel intersections , 2012, Hepatology.

[24]  M. Jung,et al.  Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. , 2012, Human molecular genetics.

[25]  Qiao Jing Lew,et al.  Identification of HEXIM1 as a Positive Regulator of p53* , 2012, The Journal of Biological Chemistry.

[26]  D. Lane,et al.  How p53 wields the scales of fate , 2012, Transcription.

[27]  B. Gao,et al.  Inflammation in alcoholic liver disease. , 2012, Annual review of nutrition.

[28]  J. Medina,et al.  An expeditious synthesis of the MDM2-p53 inhibitor AM-8553. , 2012, Journal of the American Chemical Society.

[29]  Huaxi Xu,et al.  Salubrinal attenuates β-amyloid-induced neuronal death and microglial activation by inhibition of the NF-κB pathway , 2012, Neurobiology of Aging.

[30]  C. Reis e Sousa,et al.  Signaling by myeloid C-type lectin receptors in immunity and homeostasis. , 2012, Annual review of immunology.

[31]  V. Dixit,et al.  Signaling in innate immunity and inflammation. , 2012, Cold Spring Harbor perspectives in biology.

[32]  A. Levine,et al.  The Regulation of Multiple p53 Stress Responses is Mediated through MDM2. , 2012, Genes & cancer.

[33]  Y. Ben-Neriah,et al.  Regulation of NF‐κB by ubiquitination and degradation of the IκBs , 2012, Immunological reviews.

[34]  G. Ghosh,et al.  NF‐κB regulation: lessons from structures , 2012, Immunological reviews.

[35]  M. Karin,et al.  NF‐κB and the link between inflammation and cancer , 2012, Immunological reviews.

[36]  J. Moscat,et al.  The atypical PKCs in inflammation: NF‐κB and beyond , 2012, Immunological reviews.

[37]  I. Verma,et al.  IKK biology , 2012, Immunological reviews.

[38]  S. Ghosh,et al.  Celebrating 25 years of NF‐κB research , 2012, Immunological reviews.

[39]  H. Overkleeft,et al.  Proteasome inhibitors: an expanding army attacking a unique target. , 2012, Chemistry & biology.

[40]  N. Perkins,et al.  The diverse and complex roles of NF-κB subunits in cancer , 2012, Nature Reviews Cancer.

[41]  Michael B. Mann,et al.  Using targeted transgenic reporter mice to study promoter-specific p53 transcriptional activity , 2012, Proceedings of the National Academy of Sciences.

[42]  K. Schulze-Osthoff,et al.  Translational approaches targeting the p53 pathway for anti‐cancer therapy , 2012, British journal of pharmacology.

[43]  A. Stegh.  Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils , 2012, Expert opinion on therapeutic targets.

[44]  B. Aggarwal,et al.  Suppression of pro-inflammatory and proliferative pathways by diferuloylmethane (curcumin) and its analogues dibenzoylmethane, dibenzoylpropane, and dibenzylideneacetone: role of Michael acceptors and Michael donors. , 2011, Biochemical pharmacology.

[45]  Q. Dou,et al.  Advances in the understanding of mechanisms and therapeutic use of bortezomib. , 2011, Discovery medicine.

[46]  A. Appel.  Drugs: More shots on target , 2011, Nature.

[47]  M. Groll,et al.  Proteasome structure, function, and lessons learned from beta-lactone inhibitors. , 2011, Current topics in medicinal chemistry.

[48]  B. Aggarwal,et al.  Multitargeting by curcumin as revealed by molecular interaction studies. , 2011, Natural product reports.

[49]  Sharangdhar S. Phatak,et al.  3-Formylchromone Interacts with Cysteine 38 in p65 Protein and with Cysteine 179 in IκBα Kinase, Leading to Down-regulation of Nuclear Factor-κB (NF-κB)-regulated Gene Products and Sensitization of Tumor Cells* , 2011, The Journal of Biological Chemistry.

[50]  K. Miyazawa,et al.  Dihydrotestosterone inhibits interleukin-1α or tumor necrosis factor α-induced proinflammatory cytokine production via androgen receptor-dependent inhibition of nuclear factor-κB activation in rheumatoid fibroblast-like synovial cell line. , 2011, Biological & pharmaceutical bulletin.

[51]  R. DePinho,et al.  Cancer Drug Discovery Faces the FACT , 2011, Science Translational Medicine.

[52]  A. Komar,et al.  Curaxins: Anticancer Compounds That Simultaneously Suppress NF-κB and Activate p53 by Targeting FACT , 2011, Science Translational Medicine.

[53]  A. Rizzo,et al.  Intestinal inflammation and colorectal cancer: a double-edged sword? , 2011, World journal of gastroenterology.

[54]  L. Kay,et al.  Novel proteasome inhibitors to overcome bortezomib resistance. , 2011, Journal of the National Cancer Institute.

[55]  V. Pant,et al.  Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability , 2011, Proceedings of the National Academy of Sciences.

[56]  H. Kawai,et al.  The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo , 2011, Proceedings of the National Academy of Sciences.

[57]  T. Wirth,et al.  Intestinal carcinogenesis: IKK can go all the way. , 2011, The Journal of clinical investigation.

[58]  K. Rajewsky,et al.  Constitutive IKK2 activation in intestinal epithelial cells induces intestinal tumors in mice. , 2011, The Journal of clinical investigation.

[59]  Vishva M. Dixit,et al.  Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death , 2011, Nature Reviews Molecular Cell Biology.

[60]  V. Rotter,et al.  ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters. , 2011, Omics : a journal of integrative biology.

[61]  Jeffrey Weiss,et al.  Proteasome Regulator Marizomib (NPI-0052) Exhibits Prolonged Inhibition, Attenuated Efflux, and Greater Cytotoxicity than Its Reversible Analogs , 2011, Journal of Pharmacology and Experimental Therapeutics.

[62]  Clara Abraham,et al.  Interactions between the host innate immune system and microbes in inflammatory bowel disease. , 2011, Gastroenterology.

[63]  A. Gudkov,et al.  Inflammation and p53: A Tale of Two Stresses. , 2011, Genes & cancer.

[64]  T. Gerds,et al.  PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53 , 2011, Clinical Cancer Research.

[65]  R. Benya,et al.  Phase IIa Clinical Trial of Curcumin for the Prevention of Colorectal Neoplasia , 2011, Cancer Prevention Research.

[66]  Hyung Gyun Kim,et al.  Metformin inhibits P‐glycoprotein expression via the NF‐κB pathway and CRE transcriptional activity through AMPK activation , 2011, British journal of pharmacology.

[67]  A. Dalgleish,et al.  Infection, immunoregulation, and cancer , 2011, Immunological reviews.

[68]  Di Chen,et al.  Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. , 2011, Current cancer drug targets.

[69]  P. Richardson,et al.  Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. , 2011, Current cancer drug targets.

[70]  M. Noble,et al.  Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency. , 2011, Journal of medicinal chemistry.

[71]  J. Rousset,et al.  Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides , 2010, Nucleic acids research.

[72]  Liang Xu,et al.  Natural Proteasome Inhibitor Celastrol Suppresses Androgen-Independent Prostate Cancer Progression by Modulating Apoptotic Proteins and NF-kappaB , 2010, PloS one.

[73]  P. Richardson,et al.  A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. , 2010, Blood.

[74]  Toru Ouchi,et al.  The application of Toll like receptors for cancer therapy , 2010, International journal of biological sciences.

[75]  A. Levine,et al.  p53 and NF‐κB: different strategies for responding to stress lead to a functional antagonism , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[76]  F. Kassie,et al.  Inhibition of lung carcinogenesis and critical cancer-related signaling pathways by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-l-cysteine, indole-3-carbinol and myo-inositol, alone and in combination. , 2010, Carcinogenesis.

[77]  Alexander Dömling,et al.  Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists. , 2010, Angewandte Chemie.

[78]  B. Aggarwal,et al.  Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer , 2010, International journal of cancer.

[79]  A. Komar,et al.  Inhibition of Encephalomyocarditis Virus and Poliovirus Replication by Quinacrine: Implications for the Design and Discovery of Novel Antiviral Drugs , 2010, Journal of Virology.

[80]  A. Gudkov,et al.  Pathologies associated with the p53 response. , 2010, Cold Spring Harbor perspectives in biology.

[81]  L. Staudt.  Oncogenic activation of NF-kappaB. , 2010, Cold Spring Harbor perspectives in biology.

[82]  A. Mantovani,et al.  Molecular pathways linking inflammation and cancer. , 2010, Current molecular medicine.

[83]  S. Manna,et al.  Novel Derivative of Benzofuran Induces Cell Death Mostly by G2/M Cell Cycle Arrest through p53-dependent Pathway but Partially by Inhibition of NF-κB* , 2010, The Journal of Biological Chemistry.

[84]  B. Aggarwal,et al.  Sesamin Manifests Chemopreventive Effects through the Suppression of NF-κB–Regulated Cell Survival, Proliferation, Invasion, and Angiogenic Gene Products , 2010, Molecular Cancer Research.

[85]  S. Katiyar,et al.  Molecular mechanisms of inhibition of photocarcinogenesis by silymarin, a phytochemical from milk thistle (Silybum marianum L. Gaertn.) (Review). , 2010, International journal of oncology.

[86]  B. Aggarwal,et al.  Escin, a Pentacyclic Triterpene, Chemosensitizes Human Tumor Cells through Inhibition of Nuclear Factor-κB Signaling Pathway , 2010, Molecular Pharmacology.

[87]  J. Chien,et al.  TCEAL7, a putative tumor suppressor gene, negatively regulates NF-κB pathway , 2010, Oncogene.

[88]  L. Dick,et al.  Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. , 2010, Drug discovery today.

[89]  A. Israël.  The IKK complex, a central regulator of NF-kappaB activation. , 2010, Cold Spring Harbor perspectives in biology.

[90]  M. Rolfe,et al.  Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. , 2010, Cancer research.

[91]  B. Aggarwal,et al.  NF-κB and cancer: how intimate is this relationship , 2010, Molecular and Cellular Biochemistry.

[92]  T. Hupp,et al.  The regulation of MDM2 by multisite phosphorylation--opportunities for molecular-based intervention to target tumours? , 2010, Seminars in cancer biology.

[93]  C. King.  Parasites and poverty: the case of schistosomiasis. , 2010, Acta tropica.

[94]  S. Erdman,et al.  Roles for Inflammation and Regulatory T Cells in Colon Cancer , 2010, Toxicologic pathology.

[95]  K. Gurova,et al.  New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents. , 2009, Future oncology.

[96]  T. Lawrence.  The nuclear factor NF-kappaB pathway in inflammation. , 2009, Cold Spring Harbor perspectives in biology.

[97]  Xin Huang,et al.  Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. , 2009, Journal of medicinal chemistry.

[98]  O. Lunov,et al.  Targeting NF-κB with a Natural Triterpenoid Alleviates Skin Inflammation in a Mouse Model of Psoriasis1 , 2009, The Journal of Immunology.

[99]  U. Bavendiek,et al.  Digitoxin elicits anti-inflammatory and vasoprotective properties in endothelial cells: Therapeutic implications for the treatment of atherosclerosis? , 2009, Atherosclerosis.

[100]  D. Lane,et al.  Specific activation of the p53 pathway by low dose actinomycin D: A new route to p53 based cyclotherapy , 2009, Cell cycle.

[101]  S. Dulchavsky,et al.  Immunomodulatory activity of xanthohumol: inhibition of T cell proliferation, cell-mediated cytotoxicity and Th1 cytokine production through suppression of NF-κB , 2009, Immunopharmacology and immunotoxicology.

[102]  B. Aggarwal,et al.  Inflammation and cancer: how friendly is the relationship for cancer patients? , 2009, Current opinion in pharmacology.

[103]  Hiromu Suzuki,et al.  CHFR, a potential tumor suppressor, downregulates interleukin-8 through the inhibition of NF-κB , 2009, Oncogene.

[104]  Q. Dou,et al.  Clinical development of novel proteasome inhibitors for cancer treatment , 2009, Expert opinion on investigational drugs.

[105]  S. Franceschi,et al.  Infections and cancer: established associations and new hypotheses. , 2009, Critical reviews in oncology/hematology.

[106]  P. Malfertheiner,et al.  Hepatocellular Carcinoma – Epidemiological Trends and Risk Factors , 2009, Digestive Diseases.

[107]  A. N. Anbazhagan,et al.  Green tea polyphenol epigallocatechin-3-gallate inhibits advanced glycation end product-induced expression of tumor necrosis factor-α and matrix metalloproteinase-13 in human chondrocytes , 2009, Arthritis research & therapy.

[108]  Jan Bergman,et al.  PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. , 2009, Cancer cell.

[109]  B. Zwissler,et al.  Sevoflurane and isoflurane decrease TNF-α-induced gene expression in human monocytic THP-1 cells: Potential role of intracellular IκBα regulation , 2009 .

[110]  K. Mehta,et al.  Biological and therapeutic significance of tissue transglutaminase in pancreatic cancer , 2009, Amino Acids.

[111]  M. Karin,et al.  Regulation and function of NF-kappaB transcription factors in the immune system. , 2009, Annual review of immunology.

[112]  B. Aggarwal,et al.  Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells. , 2009, Blood.

[113]  A. Komar,et al.  9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-κB and p53 pathways , 2009, Oncogene.

[114]  I. Verma,et al.  Phosphorylation of p53 by IκB kinase 2 promotes its degradation by β-TrCP , 2009, Proceedings of the National Academy of Sciences.

[115]  Yung-Hyun Choi,et al.  Sulforaphane suppresses TNF-alpha-mediated activation of NF-kappaB and induces apoptosis through activation of reactive oxygen species-dependent caspase-3. , 2009, Cancer letters.

[116]  T. Holak,et al.  c-Abl Phosphorylates Hdmx and Regulates Its Interaction with p53* , 2009, Journal of Biological Chemistry.

[117]  D. McVicar,et al.  TREM and TREM-like receptors in inflammation and disease. , 2009, Current opinion in immunology.

[118]  P. Hordijk,et al.  Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases , 2009, Journal of leukocyte biology.

[119]  M. Keogh,et al.  Ctk1 promotes dissociation of basal transcription factors from elongating RNA polymerase II , 2009, The EMBO journal.

[120]  T. Robak,et al.  Toll-like receptors and their role in carcinogenesis and anti-tumor treatment , 2008, Cellular & Molecular Biology Letters.

[121]  Luting Xu,et al.  Apigenin, a dietary flavonoid, sensitizes human T cells for activation-induced cell death by inhibiting PKB/Akt and NF-kappaB activation pathway. , 2008, Immunology letters.

[122]  B. Kerem,et al.  Introducing sense into nonsense in treatments of human genetic diseases. , 2008, Trends in genetics : TIG.

[123]  H. Namba,et al.  Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells. , 2008, Endocrinology.

[124]  L. Platanias,et al.  Curcumin suppresses constitutive activation of nuclear factor-κB and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines , 2008, Molecular Cancer Therapeutics.

[125]  K. Devarajan,et al.  5‐aminosalicylic acid inhibits colitis‐associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium‐induced colitis , 2008, Inflammatory bowel diseases.

[126]  Hae-Chul Park,et al.  Inhibition of glial inflammatory activation and neurotoxicity by tricyclic antidepressants , 2008, Neuropharmacology.

[127]  Sanjeev Banerjee,et al.  Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. , 2008, Cancer research.

[128]  K. Wiman,et al.  PRIMA-1MET Inhibits Growth of Mouse Tumors Carrying Mutant p53 , 2008, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[129]  F. Murray-Zmijewski,et al.  A complex barcode underlies the heterogeneous response of p53 to stress , 2008, Nature Reviews Molecular Cell Biology.

[130]  S. Bhattacharjee,et al.  Anti-inflammatory effect of allylpyrocatechol in LPS-induced macrophages is mediated by suppression of iNOS and COX-2 via the NF-kappaB pathway. , 2008, International immunopharmacology.

[131]  H. Mukhtar,et al.  Delphinidin inhibits cell proliferation and invasion via modulation of Met receptor phosphorylation. , 2008, Toxicology and applied pharmacology.

[132]  Judy H. Cho,et al.  Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease , 2008, Nature Genetics.

[133]  B. Aggarwal,et al.  Cancer is a Preventable Disease that Requires Major Lifestyle Changes , 2008, Pharmaceutical Research.

[134]  N. Tanaka,et al.  Activated p53 induces NF-kappaB DNA binding but suppresses its transcriptional activation. , 2008, Biochemical and biophysical research communications.

[135]  B. Aggarwal,et al.  Cancer is a Preventable Disease that Requires Major Lifestyle Changes , 2008, Pharmaceutical Research.

[136]  M. Saif.  Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008. , 2008, JOP : Journal of the pancreas.

[137]  Jen-kun Lin,et al.  Tomatidine inhibits iNOS and COX‐2 through suppression of NF‐κB and JNK pathways in LPS‐stimulated mouse macrophages , 2008, FEBS letters.

[138]  B. Aggarwal,et al.  Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. , 2008, Cancer research.

[139]  T. Evans,et al.  PMX464, a thiol-reactive quinol and putative thioredoxin inhibitor, inhibits NF-κB-dependent proinflammatory activation of alveolar epithelial cells , 2008, British journal of pharmacology.

[140]  Bharat B. Aggarwal,et al.  Pinitol targets nuclear factor-κB activation pathway leading to inhibition of gene products associated with proliferation, apoptosis, invasion, and angiogenesis , 2008, Molecular Cancer Therapeutics.

[141]  Yuan Gu,et al.  17-Acetoxyjolkinolide B irreversibly inhibits IκB kinase and induces apoptosis of tumor cells , 2008, Molecular Cancer Therapeutics.

[142]  Mihee M. Kim,et al.  Phosphorylation of MDMX Mediated by Akt Leads to Stabilization and Induces 14-3-3 Binding* , 2008, Journal of Biological Chemistry.

[143]  Nobuyuki Tanaka,et al.  p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation , 2008, Nature Cell Biology.

[144]  Y. Furuichi,et al.  A novel small-molecule inhibitor of NF-kappaB signaling. , 2008, Biochemical and biophysical research communications.

[145]  Jan Delabie,et al.  Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma , 2008, Science.

[146]  Dajun Yang,et al.  Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition , 2008, Proceedings of the National Academy of Sciences.

[147]  E. Mendis,et al.  Inhibition of inducible nitric oxide synthase and cyclooxygenase‐2 in lipopolysaccharide‐stimulated RAW264.7 cells by carboxybutyrylated glucosamine takes place via down‐regulation of mitogen‐activated protein kinase‐mediated nuclear factor‐κB signaling , 2008, Immunology.

[148]  Shangwu Chen,et al.  Toll-like receptors expressed in tumor cells: targets for therapy , 2008, Cancer Immunology, Immunotherapy.

[149]  R. Xu,et al.  Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. , 2007, Gastroenterology.

[150]  D. Kufe,et al.  MUC1 oncoprotein activates the IκB kinase β complex and constitutive NF-κB signalling , 2007, Nature Cell Biology.

[151]  D. Lane,et al.  R-Roscovitine simultaneously targets both the p53 and NF-κB pathways and causes potentiation of apoptosis: implications in cancer therapy , 2007, Cell Death and Differentiation.

[152]  A. Doseff,et al.  Apigenin Blocks Lipopolysaccharide-Induced Lethality In Vivo and Proinflammatory Cytokines Expression by Inactivating NF-κB through the Suppression of p65 Phosphorylation , 2007, The Journal of Immunology.

[153]  Lee Baker,et al.  Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator , 2007, Cancer cell.

[154]  Bulbul Pandit,et al.  Inhibitors of NF-κB derived from thalidomide , 2007 .

[155]  Pardis C Sabeti,et al.  Genome-wide detection and characterization of positive selection in human populations , 2007, Nature.

[156]  H. Allgayer,et al.  Loss of programmed cell death 4 expression marks adenoma‐carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer , 2007, Cancer.

[157]  W. Yarbrough,et al.  LZAP, a Putative Tumor Suppressor, Selectively Inhibits NF-κB , 2007 .

[158]  D. Lane,et al.  Nutlin-3 inhibits the NFκB Pathway in a p53 Dependent Manner: Implications in Lung Cancer Therapy , 2007, Cell cycle.

[159]  E. Verdin,et al.  Sirtuins: critical regulators at the crossroads between cancer and aging , 2007, Oncogene.

[160]  R. Xavier,et al.  Unravelling the pathogenesis of inflammatory bowel disease , 2007, Nature.

[161]  K. Jonscher,et al.  Acrolein Inhibits Cytokine Gene Expression by Alkylating Cysteine and Arginine Residues in the NF-κB1 DNA Binding Domain* , 2007, Journal of Biological Chemistry.

[162]  B. Aggarwal,et al.  Butein, a Tetrahydroxychalcone, Inhibits Nuclear Factor (NF)-κB and NF-κB-regulated Gene Expression through Direct Inhibition of IκBα Kinase β on Cysteine 179 Residue* , 2007, Journal of Biological Chemistry.

[163]  David Sinclair,et al.  Sirtuins in mammals: insights into their biological function. , 2007, The Biochemical journal.

[164]  Jie Zhang,et al.  Beneficial effects of losartan on vascular injury induced by advanced glycosylation end products and their receptors in spontaneous hypertension rats , 2007, Molecular and Cellular Biochemistry.

[165]  Wan-Wan Lin,et al.  A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.

[166]  S. Belinsky,et al.  A Critical Role of Luteolin-Induced Reactive Oxygen Species in Blockage of Tumor Necrosis Factor-Activated Nuclear Factor-κB Pathway and Sensitization of Apoptosis in Lung Cancer Cells , 2007, Molecular Pharmacology.

[167]  N. Perkins,et al.  p53 and NF-?B Crosstalk: IKKa Tips the Balance , 2007 .

[168]  M. Hung,et al.  Phosphorylation of CBP by IKKα Promotes Cell Growth by Switching the Binding Preference of CBP from p53 to NF-κB , 2007 .

[169]  B. Aggarwal,et al.  Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. , 2007, Blood.

[170]  T. Krieg,et al.  Inflammation in wound repair: molecular and cellular mechanisms. , 2007, The Journal of investigative dermatology.

[171]  R. Kuefer,et al.  Antagonistic effects of sodium butyrate and N-(4-hydroxyphenyl)-retinamide on prostate cancer. , 2007, Neoplasia.

[172]  H. Jäck,et al.  Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. , 2007, Cancer research.

[173]  Hyung Keun Kim,et al.  Down-regulation of iNOS and TNF-α expression by kaempferol via NF-κB inactivation in aged rat gingival tissues , 2007, Biogerontology.

[174]  S. Pyo,et al.  CML-1 inhibits TNF-α-induced NF-κB activation and adhesion molecule expression in endothelial cells through inhibition of IkBα kinase , 2007 .

[175]  J. K. Kundu,et al.  Epigallocatechin Gallate Inhibits Phorbol Ester‐Induced Activation of NF‐κB and CREB in Mouse Skin , 2007 .

[176]  D. Philpott,et al.  Nod-like proteins in immunity, inflammation and disease , 2006, Nature Immunology.

[177]  M. Colonna,et al.  The TREM receptor family and signal integration , 2006, Nature Immunology.

[178]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[179]  M. Sporn,et al.  The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-κB activation through direct inhibition of IκB kinase β , 2006, Molecular Cancer Therapeutics.

[180]  Young-Soo Hong,et al.  Inhibition of NF-κB activation through targeting IκB kinase by celastrol, a quinone methide triterpenoid , 2006 .

[181]  T. Gilmore,et al.  Inhibitors of NF-κB signaling: 785 and counting , 2006, Oncogene.

[182]  Michele Pagano,et al.  S6K1- and ßTRCP-Mediated Degradation of PDCD4 Promotes Protein Translation and Cell Growth , 2006, Science.

[183]  Y. Carmi,et al.  The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions , 2006, Cancer and Metastasis Reviews.

[184]  Klaus Heese,et al.  The Bad Guy Cooperates with Good Cop p53: Bad Is Transcriptionally Up-Regulated by p53 and Forms a Bad/p53 Complex at the Mitochondria To Induce Apoptosis , 2006, Molecular and Cellular Biology.

[185]  B. Aggarwal,et al.  Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. , 2006, Cancer research.

[186]  K. Eguchi,et al.  DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells. , 2006, International journal of oncology.

[187]  Gérard Lizard,et al.  Dihydroxyphenylethanol induces apoptosis by activating serine/threonine protein phosphatase PP2A and promotes the endoplasmic reticulum stress response in human colon carcinoma cells. , 2006, Carcinogenesis.

[188]  D. Reinberg,et al.  de FACTo Nucleosome Dynamics* , 2006, Journal of Biological Chemistry.

[189]  S. Akira,et al.  Toll-like receptors and innate immunity , 2006, Journal of Molecular Medicine.

[190]  B. Peterlin,et al.  Controlling the elongation phase of transcription with P-TEFb. , 2006, Molecular cell.

[191]  K. Chung,et al.  Validation of the Anti-Inflammatory Properties of Small-Molecule IκB Kinase (IKK)-2 Inhibitors by Comparison with Adenoviral-Mediated Delivery of Dominant-Negative IKK1 and IKK2 in Human Airways Smooth Muscle , 2006, Molecular Pharmacology.

[192]  R. Bernards,et al.  Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence , 2006, Nature Cell Biology.

[193]  Eyal Gottlieb,et al.  TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis , 2006, Cell.

[194]  Kevin M. Ryan,et al.  DRAM, a p53-Induced Modulator of Autophagy, Is Critical for Apoptosis , 2006, Cell.

[195]  Oksana Gavrilova,et al.  p53 Regulates Mitochondrial Respiration , 2006, Science.

[196]  D. Parkin,et al.  The global health burden of infection‐associated cancers in the year 2002 , 2006, International journal of cancer.

[197]  Maxwell D Cummings,et al.  Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design. , 2006, Bioorganic & medicinal chemistry letters.

[198]  V. Sasseville,et al.  Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKbeta. , 2006, Blood.

[199]  Byung Hak Kim,et al.  Suppression of interleukin-6 production in macrophages by furonaphthoquinone NFD-37. , 2006, International immunopharmacology.

[200]  R. Pazdur,et al.  United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy , 2006, Clinical Cancer Research.

[201]  A. Itai,et al.  A Novel IκB Kinase-β Inhibitor Ameliorates Bleomycin-induced Pulmonary Fibrosis in Mice , 2006 .

[202]  C. Homon,et al.  Evolution of the Thienopyridine Class of Inhibitors of IκB Kinase-β: Part I: Hit-to-Lead Strategies , 2006 .

[203]  M. Hung,et al.  Degradation of Mcl-1 by β-TrCP Mediates Glycogen Synthase Kinase 3-Induced Tumor Suppression and Chemosensitization , 2006, Molecular and Cellular Biology.

[204]  H. Grönberg,et al.  Interactions of Sequence Variants in Interleukin-1 Receptor–Associated Kinase4 and the Toll-Like Receptor 6-1-10 Gene Cluster Increase Prostate Cancer Risk , 2006, Cancer Epidemiology Biomarkers & Prevention.

[205]  S. Reddy,et al.  Oxidants and signaling by mitogen-activated protein kinases in lung epithelium. , 2006, American journal of respiratory cell and molecular biology.

[206]  J. Kutok,et al.  Spectrum of Epstein-Barr virus-associated diseases. , 2006, Annual review of pathology.

[207]  David F. Kashatus,et al.  Expression of the Bcl-3 proto-oncogene suppresses p53 activation. , 2006, Genes & development.

[208]  B. Aggarwal,et al.  Curcumin (Diferuloylmethane) Down-Regulates Expression of Cell Proliferation and Antiapoptotic and Metastatic Gene Products through Suppression of IκBα Kinase and Akt Activation , 2006, Molecular Pharmacology.

[209]  P. Oteiza,et al.  Modulation of transcription factor NF-κB in Hodgkin's lymphoma cell lines: Effect of (−)-epicatechin , 2006, Free radical research.

[210]  D. Seo,et al.  β-Carboline Alkaloid Suppresses NF-κB Transcriptional Activity Through Inhibition of IKK Signaling Pathway , 2005 .

[211]  G. Stark,et al.  Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[212]  S. Demo,et al.  Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. , 2005, Blood.

[213]  Hiroshi Yasui,et al.  A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. , 2005, Cancer cell.

[214]  Dae‐Ghon Kim,et al.  Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis. , 2005, Cancer research.

[215]  D. Lane,et al.  Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. , 2005, Cancer research.

[216]  M. Brennan,et al.  p53 is a suppressor of inflammatory response in mice , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[217]  M. Karin,et al.  NOD2 and Crohn's disease: loss or gain of function? , 2005, Immunity.

[218]  Derick R. Peterson,et al.  The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. , 2005, Blood.

[219]  N. Sagata,et al.  Beta-TrCP recognizes a previously undescribed nonphosphorylated destruction motif in Cdc25A and Cdc25B phosphatases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[220]  S. Sebti,et al.  Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. , 2005, Angewandte Chemie.

[221]  N. Perkins,et al.  ARF the Integrator: Linking NF-?B, p53 and Checkpoint Kinases , 2005, Cell cycle.

[222]  L. Staudt,et al.  MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. , 2005, Blood.

[223]  A. Mantovani,et al.  Smoldering and polarized inflammation in the initiation and promotion of malignant disease. , 2005, Cancer cell.

[224]  K. Jeng,et al.  Sesamin inhibits lipopolysaccharide-induced cytokine production by suppression of p38 mitogen-activated protein kinase and nuclear factor-kappaB. , 2005, Immunology letters.

[225]  Maxwell D Cummings,et al.  Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. , 2005, Journal of medicinal chemistry.

[226]  X. Wu,et al.  Chalcones: an update on cytotoxic and chemoprotective properties. , 2005, Current medicinal chemistry.

[227]  J. Manfredi,et al.  DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. , 2004, Molecular cell.

[228]  H. Schreiber,et al.  Inflammation as a tumor promoter in cancer induction. , 2004, Seminars in cancer biology.

[229]  M. Protopopova,et al.  Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors , 2004, Nature Medicine.

[230]  I. Adcock,et al.  The Journal of Inflammation , 2004, Journal of Inflammation.

[231]  L. Coussens,et al.  Cancer: An inflammatory link , 2004, Nature.

[232]  K. Ziegelbauer,et al.  Synthesis and structure–activity relationships of novel IKK-β inhibitors. Part 3: Orally active anti-inflammatory agents , 2004 .

[233]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[234]  Donald J Abraham,et al.  A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells. , 2004, Journal of medicinal chemistry.

[235]  M. Mayo,et al.  Modulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase , 2004, The EMBO journal.

[236]  Siyuan Zhang,et al.  Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. , 2004, Cancer letters.

[237]  M. Blagosklonny,et al.  Flavopiridol Induces p53 via Initial Inhibition of Mdm2 and p21 and, Independently of p53, Sensitizes Apoptosis-Reluctant Cells to Tumor Necrosis Factor , 2004, Cancer Research.

[238]  S. Shukla,et al.  Suppression of Constitutive and Tumor Necrosis Factor α-Induced Nuclear Factor (NF)-κB Activation and Induction of Apoptosis by Apigenin in Human Prostate Carcinoma PC-3 Cells: Correlation with Down-Regulation of NF-κB-Responsive Genes , 2004, Clinical Cancer Research.

[239]  V. Malhotra,et al.  Epigallocatechin-3-gallate, a Green Tea–Derived Polyphenol, Inhibits IL-1β-Dependent Proinflammatory Signal Transduction in Cultured Respiratory Epithelial Cells , 2004 .

[240]  M. Karin,et al.  IκB kinase-α acts in the epidermis to control skeletal and craniofacial morphogenesis , 2004, Nature.

[241]  M. Armoni,et al.  The Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression , 2004, Cancer Research.

[242]  Johanna W Lampe,et al.  Antibiotic use in relation to the risk of breast cancer , 2004, JAMA.

[243]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[244]  B. Aggarwal,et al.  Flavopiridol Inhibits NF-κB Activation Induced by Various Carcinogens and Inflammatory Agents through Inhibition of IκBα Kinase and p65 Phosphorylation , 2004, Journal of Biological Chemistry.

[245]  G. Colditz,et al.  Modifiable risk factors for cancer , 2004, British Journal of Cancer.

[246]  Paul Workman,et al.  The Cyclin-dependent Kinase Inhibitor CYC202 (R-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway , 2004, Cancer Research.

[247]  L. Sistonen,et al.  The ubiquitin‐proteasome pathway , 2004, Annals of medicine.

[248]  Richard Pazdur,et al.  Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. , 2003, The oncologist.

[249]  Michele Pagano,et al.  Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage , 2003, Nature.

[250]  N. Perkins.  Oncogenes, tumor suppressors and p52 NF-κB , 2003, Oncogene.

[251]  L. Yin,et al.  The IκB Function of NF-κB2 p100 Controls Stimulated Osteoclastogenesis , 2003, The Journal of Experimental Medicine.

[252]  Murata Toshiki.  Discovery of Novel and Selective IKK-β Serine Threonine Protein Kinase Inhibitors. Part 1. , 2003 .

[253]  J. Adams,et al.  Novel IKK inhibitors: β-carbolines , 2003 .

[254]  M. Kitagawa,et al.  Evidence that reactive oxygen species do not mediate NF‐κB activation , 2003 .

[255]  N. Perkins,et al.  p53- and Mdm2-Independent Repression of NF-κB Transactivation by the ARF Tumor Suppressor , 2003 .

[256]  M. Yao,et al.  A Selective IKK-2 Inhibitor Blocks NF-κB-dependent Gene Expression in Interleukin-1β-stimulated Synovial Fibroblasts* , 2003, Journal of Biological Chemistry.

[257]  R. Gaynor,et al.  Histone H3 phosphorylation by IKK-α is critical for cytokine-induced gene expression , 2003, Nature.

[258]  Brian D. Strahl,et al.  A nucleosomal function for IκB kinase-α in NF-κB-dependent gene expression , 2003, Nature.

[259]  A. Dalgleish,et al.  Thalidomide analogs as emerging anti-cancer drugs , 2003, Anti-cancer drugs.

[260]  E. El-Omar,et al.  The role of interleukin-1beta and other potential genetic markers as indicators of gastric cancer risk. , 2003, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[261]  F. Alt,et al.  Deficiencies of GM-CSF and Interferon γ Link Inflammation and Cancer , 2003, The Journal of experimental medicine.

[262]  T. Niki,et al.  Discovery of novel and selective IKK-beta serine-threonine protein kinase inhibitors. Part 1. , 2003, Bioorganic & medicinal chemistry letters.

[263]  R. Surabhi,et al.  TAK1 is Critical for IκB Kinase-mediated Activation of the NF-κB Pathway , 2003 .

[264]  S. Lowe,et al.  Tumor suppression by Ink4a-Arf: progress and puzzles. , 2003, Current opinion in genetics & development.

[265]  James R. Burke,et al.  BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in Mice* , 2003, The Journal of Biological Chemistry.

[266]  W. El-Deiry,et al.  Tissue-specific induction of p53 targets in vivo. , 2002, Cancer research.

[267]  W. Lichtenegger,et al.  Polymorphism of IL-1 receptor antagonist gene: role in cancer. , 2002, Anticancer research.

[268]  D. Golde,et al.  Vitamin C suppresses TNF alpha-induced NF kappa B activation by inhibiting I kappa B alpha phosphorylation. , 2002, Biochemistry.

[269]  D. Green,et al.  The Lymphotoxin-β Receptor Induces Different Patterns of Gene Expression via Two NF-κB Pathways , 2002 .

[270]  M. Goldman,et al.  Structure–Activity Relationship Studies of Ethyl 2-[(3-Methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate: An Inhibitor of AP-1 and NF-κB Mediated Gene Expression , 2002 .

[271]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[272]  N. Munshi,et al.  Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. , 2002, Blood.

[273]  G. Wahl,et al.  p53 stabilization is decreased upon NFκB activation , 2002 .

[274]  N. Munshi,et al.  NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.

[275]  B. Dave,et al.  Regulation of constitutive and induced NF-kappaB activation in malignant melanoma cells by capsaicin modulates interleukin-8 production and cell proliferation. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[276]  M. Karin,et al.  Missing Pieces in the NF-κB Puzzle , 2002, Cell.

[277]  B. Aggarwal,et al.  Thalidomide Suppresses NF-κB Activation Induced by TNF and H2O2, But Not That Activated by Ceramide, Lipopolysaccharides, or Phorbol Ester1 , 2002, The Journal of Immunology.

[278]  Galina Selivanova,et al.  Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound , 2002, Nature Medicine.

[279]  S. Ghosh,et al.  The Phosphorylation Status of Nuclear NF-ΚB Determines Its Association with CBP/p300 or HDAC-1 , 2002 .

[280]  S. Weitzman,et al.  Chronic inflammation and cancer. , 2002, Oncology.

[281]  S. Westerheide,et al.  PTEN Blocks Tumor Necrosis Factor-induced NF-κB-dependent Transcription by Inhibiting the Transactivation Potential of the p65 Subunit* , 2002, The Journal of Biological Chemistry.

[282]  E. Schmidt,et al.  IKKα Provides an Essential Link between RANK Signaling and Cyclin D1 Expression during Mammary Gland Development , 2001, Cell.

[283]  H. Clevers,et al.  APC, Signal transduction and genetic instability in colorectal cancer , 2001, Nature Reviews Cancer.

[284]  Michael Karin,et al.  Activation by IKKα of a Second, Evolutionary Conserved, NF-κB Signaling Pathway , 2001, Science.

[285]  L. Mayo,et al.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[286]  J. Bertin,et al.  CARD4/Nod1 mediates NF‐κB and JNK activation by invasive Shigella flexneri , 2001 .

[287]  Zhijian J. Chen,et al.  TAK1 is a ubiquitin-dependent kinase of MKK and IKK , 2001, Nature.

[288]  W. Liao,et al.  The essential role of MEKK3 in TNF-induced NF-κB activation , 2001, Nature Immunology.

[289]  A. Baldwin,et al.  Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity* , 2001, The Journal of Biological Chemistry.

[290]  Jiandong Chen,et al.  Activation of p53 by roscovitine-mediated suppression of MDM2 expression , 2001, Oncogene.

[291]  A. Hamilton,et al.  Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an alpha-helix. , 2001, Journal of the American Chemical Society.

[292]  C. Culmsee,et al.  A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid β‐peptide , 2001 .

[293]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[294]  C. Renner,et al.  Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. , 2001, Biochemistry.

[295]  A. Bowie,et al.  Vitamin C Inhibits NF-κB Activation by TNF Via the Activation of p38 Mitogen-Activated Protein Kinase1 , 2000, The Journal of Immunology.

[296]  A. Agrawal,et al.  The Rel Family Member P50 Mediates Cytokine-Induced C-Reactive Protein Expression by a Novel Mechanism1 , 2000, The Journal of Immunology.

[297]  H. Adami,et al.  Infections as a major preventable cause of human cancer , 2000, Journal of internal medicine.

[298]  G. Sledge,et al.  Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide , 2000, Oncogene.

[299]  H. Herschman,et al.  Identification of multiple cis‐acting elements mediating the induction of prostaglandin G/H synthase‐2 by phorbol ester in murine osteoblastic cells , 2000, Journal of cellular biochemistry.

[300]  A. Israël,et al.  Invasive Shigella flexneri Activates NF-κB Through a Lipopolysaccharide-Dependent Innate Intracellular Response and Leads to IL-8 Expression in Epithelial Cells1 , 2000, The Journal of Immunology.

[301]  X. Sun,et al.  p300/CBP-dependent and -independent transcriptional interference between NF-kappaB RelA and p53. , 2000, Biochemical and biophysical research communications.

[302]  M. Colonna,et al.  Cutting Edge: Inflammatory Responses Can Be Triggered by TREM-1, a Novel Receptor Expressed on Neutrophils and Monocytes1 , 2000, The Journal of Immunology.

[303]  T. Muta,et al.  TAK1 mediates an activation signal from toll‐like receptor(s) to nuclear factor‐κB in lipopolysaccharide‐stimulated macrophages , 2000, FEBS letters.

[304]  G. Natoli,et al.  Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase , 2000, Nature.

[305]  D. Polk,et al.  Aminosalicylic Acid Inhibits IκB Kinase α Phosphorylation of IκBα in Mouse Intestinal Epithelial Cells* , 1999, The Journal of Biological Chemistry.

[306]  E. Lane,et al.  Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B , 1999, Oncogene.

[307]  T. Ohshima,et al.  Regulatory role of endogenous interleukin-10 in cutaneous inflammatory response of murine wound healing. , 1999, Biochemical and biophysical research communications.

[308]  M. Mayo,et al.  Interleukin-10 Signaling Blocks Inhibitor of κB Kinase Activity and Nuclear Factor κB DNA Binding* , 1999, The Journal of Biological Chemistry.

[309]  H. Piwnica-Worms.  Cell cycle: Fools rush in , 1999, Nature.

[310]  R. Gaynor,et al.  Sulindac Inhibits Activation of the NF-κB Pathway* , 1999, The Journal of Biological Chemistry.

[311]  M V Chernov,et al.  A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. , 1999, Science.

[312]  W. Sandborn,et al.  Inhibition of Interleukin-1-stimulated NF-κB RelA/p65 Phosphorylation by Mesalamine Is Accompanied by Decreased Transcriptional Activity* , 1999, The Journal of Biological Chemistry.

[313]  L. Pfeffer,et al.  NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase , 1999, Nature.

[314]  Asim Khwaja,et al.  Apoptosis: Akt is more than just a Bad kinase , 1999, Nature.

[315]  J. Romashkova,et al.  NF-κB is a target of AKT in anti-apoptotic PDGF signalling , 1999, Nature.

[316]  D. Dusser,et al.  Genistein inhibits constitutive and inducible NFkappaB activation and decreases IL-8 production by human cystic fibrosis bronchial gland cells. , 1999, The American journal of pathology.

[317]  D. Gilroy,et al.  Inducible cyclooxygenase may have anti-inflammatory properties , 1999, Nature Medicine.

[318]  M. Kitagawa,et al.  An F‐box protein, FWD1, mediates ubiquitin‐dependent proteolysis of β‐catenin , 1999, The EMBO journal.

[319]  N. Perkins,et al.  Transcriptional Cross Talk between NF-κB and p53 , 1999, Molecular and Cellular Biology.

[320]  M. Naumann,et al.  INK4 cell cycle inhibitors direct transcriptional inactivation of NF-κB , 1999, Oncogene.

[321]  Michael Karin,et al.  Positive and Negative Regulation of IκB Kinase Activity Through IKKβ Subunit Phosphorylation , 1999 .

[322]  R. Inman,et al.  Rodent models of lymphocyte migration. , 1999, Seminars in immunology.

[323]  J. Ninomiya-Tsuji,et al.  The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signalling pathway , 1999, Nature.

[324]  S. Abramson,et al.  Tetracycline up-regulates COX-2 expression and prostaglandin E2 production independent of its effect on nitric oxide. , 1999, Journal of immunology.

[325]  D. Polk,et al.  Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. , 1999, Gastroenterology.

[326]  M. Mann,et al.  Identification of the receptor component of the IκBα–ubiquitin ligase , 1998, Nature.

[327]  R. Gaynor,et al.  The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β , 1998, Nature.

[328]  E. Zandi,et al.  IKK-γ is an essential regulatory subunit of the IκB kinase complex , 1998, Nature.

[329]  Michael A. Fiedler,et al.  Inhibition of TNF- α -induced NF- κ B Activation and IL-8 Release in A549 Cells with the Proteasome Inhibitor MG-132 , 1998 .

[330]  R. Hay,et al.  Defective IκBα in Hodgkin cell lines with constitutively active NF-κB , 1998, Oncogene.

[331]  S. Manna,et al.  Protein tyrosine kinase inhibitors block tumor necrosis factor-induced activation of nuclear factor-κB, degradation of IκBα, nuclear translocation of p65, and subsequent gene expression , 1998 .

[332]  R. Schmid,et al.  Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. , 1998, The Journal of clinical investigation.

[333]  G. Orphanides,et al.  FACT, a Factor that Facilitates Transcript Elongation through Nucleosomes , 1998, Cell.

[334]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[335]  J. Harley,et al.  An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. , 1997, The Journal of clinical investigation.

[336]  J. Turchi,et al.  Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. , 1997, Cancer research.

[337]  A. Ciechanover,et al.  Inhibition of NF‐κB cellular function via specific targeting of the IκB‐ubiquitin ligase , 1997 .

[338]  Matthias Mann,et al.  IKK-1 and IKK-2: Cytokine-Activated IκB Kinases Essential for NF-κB Activation , 1997 .

[339]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[340]  E. Zandi,et al.  The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. , 1997, Cell.

[341]  E. Zandi,et al.  The IκB Kinase Complex (IKK) Contains Two Kinase Subunits, IKKα and IKKβ, Necessary for IκB Phosphorylation and NF-κB Activation , 1997, Cell.

[342]  M. Gerritsen,et al.  Novel Inhibitors of Cytokine-induced IκBα Phosphorylation and Endothelial Cell Adhesion Molecule Expression Show Anti-inflammatory Effects in Vivo* , 1997, The Journal of Biological Chemistry.

[343]  David M. Rothwarf,et al.  A cytokine-responsive IκB kinase that activates the transcription factor NF-κB , 1997, Nature.

[344]  R. Tjian,et al.  Repression of p53-mediated transcription by MDM2: a dual mechanism. , 1997, Genes & development.

[345]  K. Gardner,et al.  Recruitment of p300/CBP in p53-Dependent Signal Pathways , 1997, Cell.

[346]  M. Gerritsen,et al.  CREB-binding protein/p300 are transcriptional coactivators of p65. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[347]  Norman R. Farnsworth,et al.  Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from Grapes , 1997, Science.

[348]  J. Christman,et al.  In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. , 1996, Journal of immunology.

[349]  F. Luscinskas,et al.  Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. , 1996, Journal of immunology.

[350]  S. Yamaoka,et al.  Constitutive activation of NF‐kappa B is essential for transformation of rat fibroblasts by the human T‐cell leukemia virus type I Tax protein. , 1996, The EMBO journal.

[351]  A. Ciechanover,et al.  Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[352]  T. Maniatis,et al.  Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. , 1995, Genes & development.

[353]  J. Chuang,et al.  Transcriptional Regulation by p53 , 1995, The Journal of Biological Chemistry.

[354]  L. Wang,et al.  Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. , 1994, Biochemical and biophysical research communications.

[355]  K. Rajewsky,et al.  Interleukin-10-deficient mice develop chronic enterocolitis , 1993, Cell.

[356]  R. Furth,et al.  Monocyte adherence to human vascular endothelium , 1993, Behring Institute Mitteilungen.

[357]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[358]  P. Shaw,et al.  Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[359]  D. Price,et al.  Control of formation of two distinct classes of RNA polymerase II elongation complexes , 1992, Molecular and cellular biology.

[360]  K. Kinzler,et al.  Definition of a consensus binding site for p53 , 1992, Nature Genetics.

[361]  M. Stolte,et al.  Helicobacter pylori gastritis and gastric MALT-lymphoma , 1992, The Lancet.

[362]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[363]  D. Housman,et al.  Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[364]  A. Kimchi,et al.  Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.

[365]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.

[366]  J. Arends,et al.  Helicobacter pylori and gastric carcinoma , 1990, Histopathology.

[367]  G. Nolan,et al.  Cloning of the p50 DNA binding subunit of NF-κB: Homology to rel and dorsal , 1990, Cell.

[368]  T. Gilmore.  NF-κB, KBF1, dorsal, and related matters , 1990, Cell.

[369]  S. Weiss.  Tissue destruction by neutrophils. , 1989, The New England journal of medicine.

[370]  David Baltimore,et al.  Inducibility of κ immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism , 1986, Cell.

[371]  Schwartz Da.  Helminths in the induction of cancer: Opisthorchis viverrini, Clonorchis sinensis and cholangiocarcinoma. , 1980 .

[372]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[373]  P. Rous,et al.  THE EXPERIMENTAL DISCLOSURE OF LATENT NEOPLASTIC CHANGES IN TARRED SKIN , 1941, The Journal of experimental medicine.

[374]  B. Aggarwal,et al.  Zerumbone inhibits tumor angiogenesis via NF-κB in gastric cancer. , 2014, Oncology reports.

[375]  A. Shehzad,et al.  Molecular mechanisms of curcumin action: Signal transduction , 2013, BioFactors.

[376]  U. Narayanan,et al.  Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. , 2013, Cancer research.

[377]  J. Clancy,et al.  Pharmaceuticals Targeting Nonsense Mutations in Genetic Diseases , 2012, BioDrugs.

[378]  A. Nicholson,et al.  Acid reflux and oesophageal cancer. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[379]  V. Dixit,et al.  Deubiquitinases in the regulation of NF-κB signaling , 2011, Cell Research.

[380]  B. Zwissler,et al.  Sevoflurane and isoflurane decrease TNF-alpha-induced gene expression in human monocytic THP-1 cells: potential role of intracellular IkappaBalpha regulation. , 2009, International journal of molecular medicine.

[381]  S. Akira.  Errata to "Pathogen recognition by innate immunity and its signaling" , 2009 .

[382]  F. Voss,et al.  Green tea polyphenol epigallocatechin-3-gallate inhibits advanced glycation end product-induced expression of tumor necrosis factor-α and matrix metalloproteinase-13 in human , 2009 .

[383]  H. Namba,et al.  DHMEQ, a novel NF-κB inhibitor, enhances anti-tumor activity of taxanes in anaplastic thyroid cancer cells , 2008 .

[384]  N. Perkins,et al.  p53 and NF-kappaB crosstalk: IKKalpha tips the balance. , 2007, Molecular cell.

[385]  M. Hung,et al.  Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. , 2007, Molecular cell.

[386]  N. Perkins,et al.  Integrating cell-signalling pathways with NF-kappaB and IKK function. , 2007, Nature reviews. Molecular cell biology.

[387]  W. Yarbrough,et al.  LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB. , 2007, Cancer cell.

[388]  Bulbul Pandit,et al.  Inhibitors of NF-kappaB derived from thalidomide. , 2007, Bioorganic & medicinal chemistry letters.

[389]  D. Kufe,et al.  MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling. , 2007, Nature cell biology.

[390]  Hyung Keun Kim,et al.  Down-regulation of iNOS and TNF-alpha expression by kaempferol via NF-kappaB inactivation in aged rat gingival tissues. , 2007, Biogerontology.

[391]  B. Aggarwal,et al.  Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaBalpha kinase beta on cysteine 179 residue. , 2007, The Journal of biological chemistry.

[392]  S. Pyo,et al.  CML-1 inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in endothelial cells through inhibition of IkBalpha kinase. , 2007, Journal of ethnopharmacology.

[393]  J. K. Kundu,et al.  Epigallocatechin gallate inhibits phorbol ester-induced activation of NF-kappa B and CREB in mouse skin: role of p38 MAPK. , 2007, Annals of the New York Academy of Sciences.

[394]  T. Gilmore,et al.  Inhibitors of NF-kappaB signaling: 785 and counting. , 2006, Oncogene.

[395]  C. Homon,et al.  Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. , 2006, Journal of medicinal chemistry.

[396]  Michele Pagano,et al.  S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. , 2006, Science.

[397]  M. Sporn,et al.  The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. , 2006, Molecular cancer therapeutics.

[398]  A. Itai,et al.  A novel IkappaB kinase-beta inhibitor ameliorates bleomycin-induced pulmonary fibrosis in mice. , 2006, American journal of respiratory and critical care medicine.

[399]  L. Coussens,et al.  Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.

[400]  Young-Soo Hong,et al.  Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. , 2006, Biochemical pharmacology.

[401]  D. Seo,et al.  beta-Carboline alkaloid suppresses NF-kappaB transcriptional activity through inhibition of IKK signaling pathway. , 2005, Journal of toxicology and environmental health. Part A.

[402]  Michael Karin,et al.  NF-kappaB: linking inflammation and immunity to cancer development and progression. , 2005, Nature reviews. Immunology.

[403]  Kirsty Minton.  Asthma and allergy: Pollen found guilty , 2005, Nature Reviews Immunology.

[404]  M. Karin,et al.  IkappaB kinase-alpha acts in the epidermis to control skeletal and craniofacial morphogenesis. , 2004, Nature.

[405]  B. Su,et al.  Differential regulation of interleukin 1 receptor and Toll-like receptor signaling by MEKK3 , 2004, Nature Immunology.

[406]  S. Shukla,et al.  Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[407]  Michael Karin,et al.  The IKK NF-kappa B system: a treasure trove for drug development. , 2004, Nature reviews. Drug discovery.

[408]  Yiwei Li,et al.  Mechanisms of Cancer Chemoprevention by Soy Isoflavone Genistein , 2004, Cancer and Metastasis Reviews.

[409]  B. Aggarwal,et al.  Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. , 2004, The Journal of biological chemistry.

[410]  V. Malhotra,et al.  Epigallocatechin-3-gallate, a green tea-derived polyphenol, inhibits IL-1 beta-dependent proinflammatory signal transduction in cultured respiratory epithelial cells. , 2004, The Journal of nutrition.

[411]  T. Yoshino,et al.  Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 3: Orally active anti-inflammatory agents. , 2004, Bioorganic & medicinal chemistry letters.

[412]  M. Yao,et al.  A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts. , 2003, The Journal of biological chemistry.

[413]  N. Perkins.  Oncogenes, tumor suppressors and p52 NF-kappaB. , 2003, Oncogene.

[414]  J. Adams,et al.  Novel IKK inhibitors: beta-carbolines. , 2003, Bioorganic & medicinal chemistry letters.

[415]  Michele Pagano,et al.  Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. , 2003, Nature.

[416]  R. Surabhi,et al.  TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway. , 2003, Journal of molecular biology.

[417]  K. McIntyre,et al.  BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. , 2003, The Journal of biological chemistry.

[418]  N. Perkins,et al.  p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. , 2003, Molecular cell.

[419]  D. Green,et al.  The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. , 2002, Immunity.

[420]  G. Wahl,et al.  p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. , 2002, Cancer cell.

[421]  J. Hugot.  [Role of NOD2 gene in Crohn's disease]. , 2002, Gastroenterologie clinique et biologique.

[422]  S. Ghosh,et al.  The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. , 2002, Molecular cell.

[423]  J. Hugot.  Rôle du gène NOD2 dans la maladie de Crohn , 2002 .

[424]  S. Westerheide,et al.  PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit. , 2002, The Journal of biological chemistry.

[425]  M. Karin,et al.  Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. , 2001, Science.

[426]  W. Liao,et al.  The essential role of MEKK3 in TNF-induced NF-kappaB activation. , 2001, Nature immunology.

[427]  J. Bertin,et al.  CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella flexneri. , 2001, EMBO reports.

[428]  M Elofsson,et al.  The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. , 2001, Chemistry & biology.

[429]  R. Coffman,et al.  Interleukin-10 and the interleukin-10 receptor. , 2001, Annual review of immunology.

[430]  Qian-sheng Yu,et al.  A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. , 2001, Journal of neurochemistry.

[431]  M. Karin,et al.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. , 2000, Annual review of immunology.

[432]  B. Gold,et al.  The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. , 2000, Annual review of microbiology.

[433]  A. Israël,et al.  Invasive Shigella flexneriActivates NF-kB Through a Lipopolysaccharide-Dependent Innate Intracellular Response and Leads to IL-8 Expression in Epithelial Cells , 2000 .

[434]  R. Gaynor,et al.  Sulindac inhibits activation of the NF-kappaB pathway. , 1999, The Journal of biological chemistry.

[435]  M. Mayo,et al.  Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. , 1999, The Journal of biological chemistry.

[436]  J. Romashkova,et al.  NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. , 1999, Nature.

[437]  M. Karin,et al.  Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. , 1999, Science.

[438]  Y. Xiong,et al.  HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of IkappaB and beta-catenin. , 1999, Oncogene.

[439]  N. Perkins,et al.  Transcriptional cross talk between NF-kappaB and p53. , 1999, Molecular and cellular biology.

[440]  M. Naumann,et al.  INK4 cell cycle inhibitors direct transcriptional inactivation of NF-kappaB. , 1999, Oncogene.

[441]  S. Manna,et al.  Protein tyrosine kinase inhibitors block tumor necrosis factor-induced activation of nuclear factor-kappaB, degradation of IkappaBalpha, nuclear translocation of p65, and subsequent gene expression. , 1998, Archives of biochemistry and biophysics.

[442]  W. El-Deiry,et al.  Regulation of p53 downstream genes. , 1998, Seminars in cancer biology.

[443]  E. Zandi,et al.  IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. , 1998, Nature.

[444]  R. Gaynor,et al.  The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. , 1998, Nature.

[445]  R. Hay,et al.  Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB. , 1998, Oncogene.

[446]  M. Mann,et al.  Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. , 1998, Nature.

[447]  J. Stark,et al.  Inhibition of TNF-alpha-induced NF-kappaB activation and IL-8 release in A549 cells with the proteasome inhibitor MG-132. , 1998, American journal of respiratory cell and molecular biology.

[448]  E. Zandi,et al.  A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. , 1997, Nature.

[449]  A. Ciechanover,et al.  Inhibition of NF-kappa-B cellular function via specific targeting of the I-kappa-B-ubiquitin ligase. , 1997, The EMBO journal.

[450]  D B Young,et al.  IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. , 1997, Science.

[451]  D. Knight,et al.  Feverfew: chemistry and biological activity. , 1995, Natural product reports.

[452]  V. Hu.  The Cell Cycle , 1994, GWUMC Department of Biochemistry Annual Spring Symposia.

[453]  A. Aceti,et al.  Helicobacter pylori and gastric carcinoma. , 1993, The Journal of infection.

[454]  G. Nolan,et al.  Cloning of the p50 DNA binding subunit of NF-kappa B: homology to rel and dorsal. , 1990, Cell.

[455]  D. Baltimore,et al.  Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. , 1986, Cell.

[456]  D. Schwartz.  Helminths in the induction of cancer: Opisthorchis viverrini, Clonorchis sinensis and cholangiocarcinoma. , 1980, Tropical and geographical medicine.